Cataract – also known as cataract – is an eye disease that usually begins in middle age, around the age of 50, and is the most common cause of blindness if left untreated. In people with an advanced cataract, a gray tint can be seen behind the pupil.
Cataracts are the most common eye disease: between the ages of 50 and 65, about half of the population is affected. From around 65 years of age, it affects almost everyone. Cataract surgery is therefore one of the most frequently performed procedures: it is performed almost 15 million times a year worldwide.
In this case, the operation is performed by surgically replacing the clouded natural lens with a state-of-the-art artificial lens (intraocular lens) on an outpatient basis – usually with a multifocal lens or, alternatively, a monofocal lens. Our ophthalmologists at EuroEyes clinics have successfully performed several thousand cataract surgeries. The revolutionary LenSx® laser technology even enables blade-free implantation.
Depending on the intensity and position of the cataract in the eye, symptoms vary in those affected. Cataracts usually affect both eyes, but can also affect only one, which is considered a higher risk for long-term damage.
Early-stage cataracts are most often detected by a slit-lamp examination at the ophthalmologist’s office, without any symptoms to date. The question of how quickly cataracts progress cannot be answered in general terms. In some cases it takes many years before the disease leads to blindness if left untreated, while in others it progresses rapidly within a few weeks. In the advanced stage, the following symptoms usually appear in varying degrees, indicating cataracts:
Vision deteriorates in near and/or distance vision: Vision becomes more strained.
Vision becomes increasingly blurred: Vision as if through fog or a veil.
The vision of colors, contours and contrasts deteriorates: everything becomes dull and pale.
Glare sensitivity (nyctometry) increases: When light hits the retina, for example from oncoming traffic while driving at night, vision is severely impaired.
Light-dark adaptation worsens: It takes longer and longer to become accustomed to changing between light and dark environments.
Double vision is perceived: One suddenly sees double, similar to alcohol consumption.
Spatial vision (stereopsis) deteriorates: Due to poor depth perception, for example, falls are more likely and climbing stairs becomes a challenge.
Cataracts become visible: A grayish or whitish clouding can be seen on the lens.
In addition to cataract, visual impairments such as age-related macular degeneration (AMD) can also occur around the age of 70. Regular ocular fundus checks must therefore be taken very seriously. Now you can do the self-test with the Amsler grid: Macular Degeneration (AMD) self-test
Driving a car with cataracts is only permitted as long as vision is at least 70 percent. If the visual acuity is less than this, an ophthalmologist’s certificate must be available that certifies the ability to drive. If vision falls below 50 percent, driving is generally no longer permitted. With cataracts, this can quickly become the case. In order for you to be mobile again and thus independent of public transportation, cataract surgery may be useful to restore your vision.
A long-term study of about 5500 people found that the risk of dementia is reduced by almost 30 percent when people undergo cataract surgery. The researchers emphasize that no other treatment has so far been shown to have such a strong protective effect with regard to dementia. One of the reasons for this may be the general decrease in the transmission of neuronal impulses to the brain in cataracts. Withdrawal from sports and other activities is also frequently observed in people suffering from cataracts and promotes the development of senile dementia.
So cataract surgery not only increases your enjoyment of life, but also reduces your risk of developing dementia.
The good news first: cataracts are curable! Although there is no medication for cataract treatment and without treatment the lens clouding increases to the point of blindness, cataract surgery permanently solves the problem and completely restores vision. In addition, additional vision aids due to age-related farsightedness or other refractive errors are also no longer necessary after eye lens surgery with the use of a multifocal lens. The right time for cataract surgery has come at the latest when limitations in everyday life due to diminishing vision appear.
The surgery is performed on an outpatient basis and usually takes 15 minutes per eye. Before the procedure, the eye is anesthetized with drops so that the patient does not feel any pain during lens replacement. The eye is opened with a tiny corneal incision, which heals seamlessly.
The anterior lens envelope is opened in a circular fashion. Then the lens core is removed. The rest of the lens envelope remains and serves as a ‘holding apparatus’ for the new lens.
The surgeon inserts the new lens into the eye with an injector. The lens unfolds and is properly placed in the empty lens case by the surgeon. It can remain in the eye for life and can be either monofocal or multifocal. Because a monofocal lens has only one focal point, the patient is still dependent on glasses after surgery. A multifocal lens, on the other hand, has multiple focal points. It enables sharp vision at different distances and thus a spectacle-free life.
Cataract treatment can be done with monocular or multifocal lenses. Multifocal lenses have multiple focal points. The decisive advantage is that after the treatment the patient can see sharply again at near and middle distance as well as at a distance and is no longer dependent on reading glasses or varifocals. In contrast, monofocal lenses have only one focal point. They can therefore only improve vision either near or far. Complete independence from glasses cannot be guaranteed with monofocal lenses.
The optics of the multifocal lenses used at EuroEyes are manufactured with the aid of patented SMP technology: a special process reduces stray light phenomena, which always occur with multifocal lenses, to an absolute minimum. The positive effect: less glare and fewer halos (light rings). In addition, the aspherical optics ensure optimized image quality and improved contrast vision under reduced light conditions, such as at dusk or at night.
To protect the sensitive retina, the lenses are optionally equipped with an extended light protection filter in addition to a UV filter. This protective function is used in ophthalmology, especially for the prevention of macular degeneration (AMD) or for patients who are already affected by AMD.
Measurement of all relevant eye parameters
Diagnosis whether you are suitable for cataract surgery
In-depth consultation
Intensive preliminary ophthalmological examination and measurement of your eyes
Detailed treatment explanation by a medical specialist
Duration of examination usually 2 hours
Before this appointment you are not allowed to wear soft contact lenses for one week and hard contact lenses for two weeks
You will receive an aftercare kit for the days following your treatment. The contents and medication will be explained to you in detail by our staff.
Please bring someone to accompany you
We recommend that you wear comfortable clothing
Please refrain from wearing perfume and make-up on the day of your lens treatment
You can eat and drink regularly on the day of treatment, please do not smoke.
The total duration of this outpatient surgery is 10 – 15 minutes per eye.
The operated eye is protected by an eye bandage until the next day.
By the way: If it is about both eyes, we usually treat them on two consecutive days.
By the way: if both eyes are involved, we usually treat them on two consecutive days.
Please do not rub your eyes
Apply eye drops several times a day as directed by a doctor
Use artificial tears as needed
Professional activity after 2-4 days
Sports activities possible after approx. 3 days, avoid swimming and sauna in the beginning
Controls are usually: after 1 day – 1 week – 1 month – 3 months
Driving a car is allowed again only after permission of the doctor
The femtosecond laser LenSx® enables blade-free implantation of artificial lenses for the treatment of cataracts for the first time – and is thus revolutionary in this sector. Several steps of the previous surgical method are combined in this laser lens surgery, making the surgeon’s scalpel unnecessary. The laser offers two major advantages over the previous method: Firstly, greater precision thanks to more exact positioning of the artificial lens during lens replacement. On the other hand, greater safety thanks to high-precision laser cuts.
EuroEyes is one of the first clinic groups and competence center for lens surgery in Germany to use the LenSx® in the field of laser lens exchange and now offers it at many locations – once again demonstrating a pioneering spirit. Because only the most modern and gentle methods are in line with the philosophy of EuroEyes: not only to correct your refractive error, but to constantly improve the quality of your treatment as well as the quality of your vision.
EuroEyes has long-term experience in the treatment of cataracts. Thanks to the outstanding pioneering position of Dr. Jørn Jørgensen in the field of cataract surgery: As early as 1990, he succeeded in being the first eye surgeon in Hamburg to perform cataract surgery on an outpatient basis – using a new small incision technique (phacoemulsification)- and less than a year later introduced “surgery without sutures”, EuroEyes has unique and incomparable experience in the treatment of cataracts.
With Dr. Jørn Jørgensen, EuroEyes is led by a pioneer in the field of cataract surgery. In 1990 he was the first eye surgeon in Hamburg to perform outpatient cataract surgeries with a new micro-incision technique (phacoemulsification). Less than a year later, Dr. Jørgensen introduced the “no-stitch surgery”. Thus, EuroEyes has a unique and unmatched experience in the field of cataract treatments. We have successfully performed several thousand cataract surgeries in our EuroEyes clinics.
Years of experience
Clinics in Global
Clinics in Europe
Clinics in the PRC
At EuroEyes, cataract surgery with a simple monofocal lens costs from 2,700 euros per eye and with a multifocal lens or trifocal lens from 3,300 euros per eye. The multifocal lenses cure not only cataract, but also any other existing defective vision, no visual aid is needed afterwards.
Cataract surgery with the use of monofocal lenses is fully covered by the statutory health insurance (GKV) as well as by most private health insurances (PKV). Only additional examinations prior to lens surgery, such as biometry by laser or coherence tomography, are additional services that must be paid for by the statutory health insurance as IgeL services.
The use of multifocal lenses or trifocal lenses is not a statutory health insurance benefit and must be paid for by the patient. However, many private health insurances cover the costs for multifocal lenses completely or at least proportionally. It is best to contact your health insurance company directly.
In principle, you can deduct the surgical correction of your defective vision to improve your work performance from your taxes as an extraordinary burden within the meaning of § 33 EStG.
Immediately after the diagnosis is made and at the latest when the first limitations of vision lead to disabilities in everyday life.
Cataracts do not go away on their own and cannot be treated with medication. Without cataract surgery, vision continues to deteriorate and, in the worst case, can lead to complete blindness.
Cataract surgery takes about 15 minutes per eye.
Local anesthesia (often even just a drip anesthesia) makes the eye and its surroundings insensitive, so that the procedure hardly causes any pain.
If desired, patients can receive a light twilight sleep anesthesia with us during cataract surgery.
Side effects of cataract surgery can be reddened or bloodshot eyes, which usually disappear completely after a few days. Sometimes, so-called dry eyes can occur, in which the eyes are no longer sufficiently moistened with tear fluid. In this case, the temporary use of eye drops helps. This side effect also usually disappears after some time.
Do not rub the eyes! After the ointment dressing is removed the day after the cataract surgery, the prescribed antibiotic eye drops to prevent infections and anti-inflammatory eye drops must be applied several times a day as instructed by the attending physician for a period of up to four weeks. It is essential to attend the follow-up appointments the day after cataract surgery and one week, one month and three months later.
Hair washing is possible again after only two days. Swimming and sauna should be suspended for six to eight weeks until complete healing is permitted by the attending ophthalmologist. Light sports are usually possible again after three days and regular sports after about one week.
After cataract surgery, one can usually return to work after two to four days. If the work involves driving, flying or operating heavy machinery, the attending physician must determine for each individual case how long the inability to work will last.
Driving a car is usually possible again after cataract surgery after one week. However, the doctor must give permission for this, as it can also take longer from case to case.
Make-up and cosmetic products in the eye area should be avoided completely for at least four, preferably six to eight weeks.
Since the artificial lens cannot wear out or become cloudy, it will last a lifetime unless it is damaged in an accident.
In most cases, after cataract surgery, one is permanently cured of cataracts and, if a multifocal lens was inserted, also permanently free of glasses and contact lenses. In rare cases, a haze may form on the lens, the so-called secondary cataract. This can be quickly removed by an uncomplicated laser eye treatment. Those who have opted for the use of monofocal lenses during cataract surgery can later have them replaced with multifocal lenses, which, however, involves a second lens surgery.
No. Unlike a contact lens, there is no need to worry about foreign body sensation or even intolerance with an artificial lens.
The artificial lens is made of very well tolerated plastic, rejection reactions practically do not occur.
During the multifocal operation the old intraocular lens is partly replaced by a new multifocal lens implant which make it possible for you lifelong to see far, near and intermedia without glasses. During the operation the old lens is only partly removed leaving the old lens-capsula in the eye, serving as a bag positioning and keeping the new lens exactly at the right place in the eye. At the time of surgery this “old” bag is totally clear and visible. During the next weeks to months after the operation this bag may develop a little haze (secondary cataract), The patient may feel that the vision for far or for near become a little blurry. If you feel this should be the case please contact us. We will very easily to be able with a small light beam to remove the haze and you will fell immediately an improvement.
Follow us on social media:
Mr Philip Duncan Wright
Appointed as our independent non-executive Director on 25 March 2019. He is mainly responsible for financial oversight and supervising and providing independent advice to the Board.
Mr Wright has more than 35 years of experience in the fields of accounting and finance. He has been a member of the Institute of Chartered Accountants in England and Wales since January 1979. He was formerly a partner of Price Waterhouse (“PW”) from July 1987 to June 1998 and of PricewaterhouseCoopers (“PwC”) from July 1998 to December 2011. During his time with PW in Germany, he served as partner in charge of corporate finance and recovery from August 1990 to August 1994, and partner in charge of Berlin from July 1993 to August 1994 and partner in charge of business development for assurance and audit of PW Europe from September 1994 to June 1998. At PwC, he served as partner in charge of corporate finance and recovery in Europe, Middle East and Africa from July 1998 to September 2000, partner in charge of global corporate finance and recovery as well as a member of the Global Executive of PwC from October 2000 to October 2003. From November 2003, Mr Wright became a global relationship partner of PwC UK and was the chairman of their non-executive director program up until December 2011 when he retired from the partnership of PwC.
Mr Wright has vast experience in assuming public and charitable roles which have included several positions in relation to the public health sector. He served as a non-executive director of the National Health Service (“NHS”) London (Strategic Health Authority) from October 2009 to July 2010. Thereafter, he assumed the positions of non-executive director and the chair of the audit committee of Barts and the London NHS Trust from November 2010 to March 2012 and then assumed the same positions in Barts Health NHS Trust from April 2012 to March 2015. From April 2015 to August 2015, Mr Wright served as acting chairman of Barts Health NHS Trust. He was also a trustee and director of The Common Purpose Charitable Trust, a charity and social enterprise based in the United Kingdom which is engaged in leadership management from May 2007 to January 2018. Mr Wright was a council member of Goldsmiths College, University of London, from March 2012 to August 2017 and the chairman of their audit committee from September 2013 to August 2017. From February 2009 to October 2015, Mr Wright was also the chairman and director of Digital Theatre.com Limited, a company which is engaged in the online media sector.
Mr Wright has been a non-executive director and chair of the audit committee of Allia Limited, a communal benefit society, since October 2012. He is also a non-executive director and the chairman of the audit committee of Retail Charity Bonds Plc, which helps charitable organisations to raise unsecured loan finance, since March 2014 and a non-executive director of Beyond Food Community Interest Company, a social enterprise, since April 2016.
The major duties of the audit committees of the public bodies and companies named above include, among other things, reviewing financial statements and management response to the findings of internal and external auditors; monitoring and ensuring the effectiveness of the risk management, internal control and governance arrangements.
Mr Wright obtained his Bachelor of Arts degree from Christ Church of the University of Oxford in the United Kingdom in July 1975 and was conferred a Master of Arts degree from the same university in May 1980.
Ms. Katherine Rong Xin
Ms. Xin, graduated from Auhui University (安徽大學) in July 1984 with a bachelor’s degree in English. She obtained a master’s degree in applied linguistics from Graduate University of Chinese Academy of Sciences (中國科學院研究生院) in July 1986, and a master’s degree in business administration from California State University in June 1991. She further obtained a doctor’s degree in business administration from the University of California in June 1995.
Currently, Ms. Xin is an independent non-executive director of Fosun Tourism Group (a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 1992)) and E Fund Management Co. Ltd. (a company established in Guangzhou, China with limited liability), respectively. She has been a professor of management since September 2001 and Associate Dean since 2011 at the China Europe International Business School (中歐國際工商學院). From August 2006 to December 2009, Ms. Xin worked as a professor of management at the International Institute for Management Development in Lausanne, Switzerland . She worked as an associate professor of management at The Hong Kong University of Science and Technology from September 1999 to August 2001. From September 1995 to August 1999, she served as an assistant professor of management at the University of Southern California. Ms. Xin served as an independent director in Shanghai Blossom Hill Hotel Management Co. Ltd., (上海布洛斯酒店管理有限公司), a company mainly engaged in boutique hotel management in China under the Blossom Hill (花間堂) brand, from March 2012 to April 2017. Ms. Xin was awarded the Chinese Most Cited Researchers by Elsevier, a global provider of scientific, technical, and medical information, for six consecutive years from 2014 to 2019.
Ms. Xin has entered into a letter of appointment with the Company for a term of two years. She will hold office until the next annual general meeting of the Company and is thereafter subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Ms. Xin will be entitled to receive an annual director’s fee of HK$360,000 which is determined by the Board based on the recommendation of the remuneration committee of the Board and by reference to her duties and responsibilities and prevailing market conditions.
Save as disclosed above, Ms. Xin does not hold any directorship in any other listed public companies, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years and does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company. As at the date of this announcement, Ms. Xin does not have any interest or short position in the shares, underlying shares and/or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong (“SFO”).
Ms. Xin has confirmed that she has met the independence criteria as set out under Rule 3.13 of the Rules Governing the Listing of Securities on the Stock Exchange (“Listing Rules”). Save as disclosed above, there are no other matters relating to Ms. Xin’s appointment which need to be brought to the attention of the shareholders of the Company and there is no information to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules.
The Board extends its warm welcome to Ms. Xin.
Mr Hans Helmuth Hennign
Appointed as our independent non-executive Director on 25 March 2019.
Mr Hennig has been working with Jebsen & Co. Ltd. (“Jebsen”), a privately-held marketing, distribution and investment company established in Greater China, since September 1983. In May 1990, Mr Hennig was promoted to the role of General Manager-Corporate Development of Jebsen where he was responsible for developing the business strategy of the Group. He was then further appointed as a director of the board of directors of Jebsen in January 1994. In January 1997, Mr Hennig became group deputy managing director of Jebsen up until March 2000 when he assumed his present position as group managing director of Jebsen, where he is responsible for the overall business operations, strategies and development of Jebsen.
Mr Hennig graduated with his Danish Studentereksamen (high school diploma equivalent) from Deutsches Gymnasium für Nordschleswig, Aabenraa, Denmark in June 1977. He further completed the thirty fifth executive development program at the executive development center of the College of Commerce and Business Administration of the University of Illinois at Urbana-Champaign in the United States in June 1987. Mr. Hennig was appointed a guest professor by Jilin University, People’s Republic of China in June 2012.
Mr Marcus Huascar Bracklo
First joined our Group in July 2012 and was appointed a non-executive Director on 25 March 2019, and is primarily responsible for advising on strategy and business development of our Group. He is also a director of Shanghai Deshijia and Beijing Deshijia, both of which are subsidiaries of our Company.
Mr Bracklo has over 25 years of experience in the healthcare sector, specialising in corporate finance, accounting and mergers and acquisitions. From October 1987 to August 1998, he worked at Price Waterhouse (now known as PricewaterhouseCoopers), starting as a trainee accountant, and was admitted to partnership in June 1997. From April to December 1992, he was seconded to the Directorate for Financial and Enterprise Affairs of Organisation of Economic Co-operation and Development, being primarily responsible for providing privatisation and accounting reform advice in central and eastern Europe. In October 1998, he was admitted to the partnership of Arthur Andersen as their head of healthcare in Europe during which he was primarily responsible for cross-border mergers and acquisitions in the healthcare industry. From December 2001 to September 2007, he was managing director of investment bank Sal. Oppenheim. Jr. & Cie. AG & Co. KgaA and a member of their investment banking committee where he was primarily responsible for their investment banking business in the healthcare industry. He is a director and founder of Baigo Capital GmbH, an advisory and investment firm specialising in the healthcare sector, which he founded in October 2008. He concurrently assumed the role of chief executive officer at Vanguard AG, a re-processor of medical devices from December 2011 to November 2015. Since January 2010, he has been a non-executive director of Lohfert & Lohfert AG, a healthcare consultancy firm.
Mr Bracklo obtained his Bachelor’s degree in Economic Science from University College London, United Kingdom in August 1986. He further obtained his Master’s degree in Economic Science from the London School of Economics, United Kingdom in November 1987. He became a chartered accountant in the United Kingdom in 1990 and was appointed a German public auditor (Wirtschaftsprüfer) in Germany in January 1995.
Mr Jannik Jonas Slot Jørgensen
Joined our Group in March 2012 and was appointed our executive Director on 25 March 2019, and is primarily responsible for supervising and overseeing the business development and marketing of the business in Denmark and the PRC. Mr Jørgensen is also a director of Guangzhou Deshijia, a subsidiary of our Company. He is the son of Dr Jørgensen, our chairman, executive Director, chief executive officer and Controlling Shareholder of the Company.
Prior to joining our Group, Mr Jørgensen interned and worked in ophthalmological and marketing sectors on a part-time basis. He was an intern at our eye clinic in Copenhagen, Denmark from January to July 2011, and was also an intern at Moorfields Eye Hospital in London, United Kingdom from August to December 2011. Since February 2014, he has been a marketing manager at our marketing department in the PRC. From May to July 2015, he interned at the ophthalmology department at Instituto Zaldivar, an ophthalmological centre in Mendoza and Buenos Aires, Argentina. From May to July 2017, he interned in the emergency department of Tygerberg Hospital in Cape Town, South Africa. He was also a marketing manager overseeing the marketing department of our eye clinics in the PRC from April to August 2017. Since August 2018, he has also been a resident doctor at the department of abdominal surgery at Randers Hospital in Denmark.
Mr Jørgensen obtained a Bachelor’s degree in Human Medicine from Aarhus University in Denmark in January 2015. He further obtained a Master’s degree in Human Medicine from Aarhus University, Denmark in June 2018.
Dr Ralf-Christian Lerche
Worked with our Group since April 2005 and was appointed our executive Director on 25 March 2019, and is primarily responsible for supervising and overseeing the recruitment of doctors, handling patients’ complaints and advising on medical trends and practice. He also moderates the discussion and scientific round at our annual doctors meeting and oversees our medical operations. Dr Lerche is a freelancer and has entered into a contract for service with the Group.
Dr Lerche has over 20 years of experience as a practicing ophthalmologist. Since October 1998, he has been a consultant in ophthalmology in Ärztekammer Hamburg, a medical association which represents the medical profession in Hamburg, Germany. He was also a senior doctor in the university eye clinic of Otto-von-Guericke University Magdeburg, Germany from July 2000 to August 2002. From September 2002 to March 2005, he was a senior doctor and head of department for refractive surgery at the university eye clinic of the University of Hamburg, Germany. Since April 2005, he has been a self-employed ophthalmologist in Hamburg, Germany and has been working in Dr Jørgensen & Partners, an eye clinic which specialises in corneal and cataract surgery. Since June 2007, he has been an associate medical director at EuroEyes AugenLaserZentrum Hannover GmbH, a subsidiary of our Company. In July 2013, he founded Ophthalmologikum Dres. Jørgensen Lerche Galambos Klär-Dißars GmbH, an eye clinic which specialises in general and retinal ophthalmology. In March 2016, Dr Lerche further founded MVZ Ophthalmologikum Eidelstedt GmbH, an eye clinic which specialises in general and retinal ophthalmology in Hamburg, Germany. He became the president of VSDAR in January 2018.
Dr Lerche obtained his medical degree in Ophthalmology from University of Göttingen, Germany in October 1995 and became a qualified medical doctor in Hamburg, Germany in February 1996. He further obtained his habilitation degree in Ophthalmology from the University of Hamburg, Germany in February 2005 and was recognised as an associate professor who is capable of conducting self-contained university teaching in April 2005.
Dr Markus Braun
Joined our Group in October 2018 and is primarily responsible for supervising and overseeing the overall financial and accounting management of our Group. He was appointed a Director on 14 December 2018 and subsequently redesignated as an executive Director on 25 March 2019.
From April 2015 to October 2018, Dr. Braun was the vice president IFRS Compliance of Schaeffler AG, a global automotive and industrial manufacturer, primarily responsible for its group wide accounting related matters as well as matters pertaining to the internal control system. Before that, he worked for Deutsche Telekom group, a German telecommunication company, in different finance-related functions from December 2003 until March 2015, first serving in the parent company, Deutsche Telekom AG, and subsequently in its wholly-owned subsidiary, Deutsche Telekom Accounting GmbH, which is the global accounting shared service center for Deutsche Telekom group, where he was responsible for the accounting-related processes from transactional accounting to consolidation from 2010 onwards. At Deutsche Telekom, Dr Braun served as the senior vice president service management from June 2010 to April 2014 where he was responsible for managing main support functions for example business controls, project management or compliance management. Thereafter, he assumed the position of senior vice president business development from May 2014 to March 2015 whereby he was responsible especially for the business development of the subsidiary.
Dr Braun obtained his diploma in Business Administration in October 1998 and his Doctorate of Economics in June 2005 from the University Of Passau, Germany. Dr Braun completed the CPA exam in the University of Illinois, United States and has been a certified public accountant of the State of Illinois, United States since November 2000.
Dr Jørn Slot Jørgensen
Appointed a Director on 13 August 2018 and subsequently re-designated as an executive Director, and appointed as chairman of the Board, on 25 March 2019. He is also a founder of our Group and is mainly responsible for formulating our overall development strategies and business plans and overseeing the management and strategic development of our Group.
Dr Jørgensen has over 30 years of experience of practice as an ophthalmologist. Prior to founding our Group, he practiced medicine in clinics and hospitals (both private and public) between 1987 and 1991.
The list below sets out Dr Jørgensen’s major engagements in various professional associations and organisations:
Member of American Society of Cataract and Refractive Surgery since December 2002
Member of European Society of Cataract and Refractive Surgeons from April 2010 to March 2016
Member of Professional Association of German Ophthalmologists (BVA) since 1992
Member of the board, vice president and president of Association of Specialty Clinics for Eye Laser and Refractive Surgery (VSDAR) since 2004
Dr Jørgensen has received numerous awards and recognitions for his achievement, including (i) the “Hans-Sautter-Laureate” awarded by the Vereinigung Norddeutscher Augenärzte in 1987, and (ii) inclusion into the “Best Doctors List” under the category of “Experts for Refractive and Cataract Surgery” in “FOCUS”, a German magazine from 2012 to 2018.
Dr Jørgensen passed his medical examination at Odense University, Denmark in July 1974. He was a registrar at the University Medical Centre Hamburg-Eppendorf* in Germany from 1982 to 1986 and he had undertaken intensive training in refractive laser surgery at the Neumann Eye Institute in Deland, Florida in the United States in 1990.
Join our Newsletter